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INTRODUCTION
Most women with epithelial ovarian cancer (EOC) treated
with current, taxane-platinum-based combination chemother-
apy regimens will respond to first-line chemotherapy (1).
Nonetheless, complete clinical or pathological responses have
not necessarily translated into long-term disease control or
cure. Data from several first-line chemotherapy trials show
that, even with the most advanced treatments, 60-70% of
patients with advanced ovarian cancer will recur (2, 3).
The management of tumor recurrence remains a clinical
challenge, since in the platinum-resistant population the
chance of response to a secondary treatment is currently less
than 20% (4). Several single chemotherapeutic agents have
been used in this setting and have demonstrated modest activ-
ity such as topotecan (5, 6), gemcitabine (7, 8), liposomal
doxorubicin (9), vinorelbine (10), oral etoposide (11, 12), and
ifosfamide (13). It cannot be overemphasized the importance
of clinical trials to identify agents active in this group of resis-
tant patients. 
Etoposide is a semisynthetic glucosidic derivative of podo-
phyllotoxin. The inhibition of DNA topoisomerase II is known
to be a major mechanism of action. In refractory ovarian can-
cer, response rate (RR) with single agent etoposide have been
reported to be less than 15% (14, 15). 
Ifosfamide is a part of nitrogen mustard’s alkylating agents.
It has often been used as a single agent or in combination in
EOC patients refractory or resistant to cisplatin (16). The RR,
common to various studies, was between 12 and 25%, with
a median of 20%. The progression-free survival (PFS) was
between 4 and 6 months, and the overall survival (OS) bet-
ween 7 and 11 months. Ifosfamide was active in patients refrac-
tory to cisplatin and also in patients already treated with cyclo-
phosphamide, suggesting the absence of cross-resistance (17).
Very little information is available to combination chemo-
therapy as salvage treatment of EOC after more than two
chemotherapy regimens. Etoposide and ifosfamide are one
of the oldest drugs demonstrating clinical antitumor activi-
ty and relatively worldwide spread. In various animal tumors,
etoposide has shown synergy with cyclophosphamide (18).
Additionally, the combination of etoposide and ifosfamide
(ETI) has also been demonstrated to be an effective regimen
in solid neoplasms such as small cell lung cancer (14). In the
field of EOC, several phase II studies were reported. Some
indicated reasonable efficacy and another (19) showed dismal
results which included only ‘‘true’’ platinum-resistant pati-
The aim of this trial was to investigate the efficacy and toxicity of combination che-
motherapy with etoposide and ifosfamide (ETI) in the management of heavily pre-
treated recurrent or persistent epithelial ovarian cancer (EOC). Patients with recur-
rent or persistent EOC who had measurable disease and at least two prior chemo-
therapy participating in this phase II trial were to receive etoposide at a dose of 100
mg/m
2/day intravenously (IV) on days 1 to 3 in combination with ifosfamide 1 g/m
2/
day IV on days 1 to 5, every 21 days. Thirty-seven patients were treated; about 78%
had previously received more than two separate regimens. The response rate (RR)
was 18.9% and median duration of response was 7 months (range, 1-15). Treat-
ment free interval prior to ETI (TFI) has significant correlation with RR rate (P=
0.034). Patients (n=6) with TFI ≥6 months had 50% of RR, while patients (n=31)
with TFI <6 months had 12.9%. Median survival was 9 months at a median follow-
up of 9.2 months. Grade 3 or 4 toxicities included neutropenia in 20.1% of the 139
cycles of ETI, anemia in 7.2% and thrombocytopenia in 8.6%. The ETI produces
relatively low toxicity and modest activity in heavily pretreated recurrent or persis-
tent EOC. This is significant in patients with TFI ≥6 months.
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Accepted : 31 October 2008ents. However, there is no study on ETI in patients with heav-
ily pretreated EOC patients. 
Therefore, this phase II clinical study was designed to evalu-
ate the efficacy and toxicity of 5-day regimen of ETI in pati-
ents with heavily pretreated EOC patients.
MATERIALS AND METHODS
Eligibility criteria for enrollment on this study included
patients with histologically confirmed EOC treated with two
or more prior chemotherapy regimens after primary cytore-
ductive surgery. Patients should have measurable disease on
computerized tomography (CT) or magnetic resonance image
(MRI) when first administration of ETI. Other eligibility cri-
teria included no previous treatment with either ifosfamide or
etoposide, normal end-organ function, WBC count of 3,000/
μ L or higher, platelet count of 100,000/μ L or higher, granu-
locyte count of 1,500/μ L or higher, a serum creatinine with-
in institutional normal limits, hepatic enzymes (SGOT, SGPT
and alkaline phosphatase) less than or equal to three times
the upper level of institutional norm and bilirubin less than
or equal to 1.5 times the upper level of institutional norm,
and a Karnofsky performance score greater than 60%. In-
formed consent was obtained according to the guidelines of
our hospital Institutional Review Boards.
Patients received ifosfamide 1 g/m2/day on days 1 to 5 as
an intravenous (IV) infusion in 500 mL 5% dextrose solution
over 1 hr in association with adequate hydration and mesna
uroprotection. Etoposide was given at a dose of 100 mg/m2/
day IV on days 1 to 3 over 1 hr. Cycles were repeated every
3 weeks and at least two courses were given to all patients,
while a minimum of four courses were given to responders.
Delay of treatment was permitted if there was hematologi-
cal toxicity greater than grade 3 during the previous cycle.
A 25% dose reduction of ETI was required for grade 4 throm-
bocytopenia or grade 4 neutropenia with fever. Toxicity eval-
uations were conducted just before next treatment cycle by
performing a complete blood count, urinalysis, renal and liver
function tests, and a performance status evaluation. Toxicity
was defined according to WHO standard criteria. The pati-
ents’ response to treatment was assessed every two cycles by
imaging techniques and every cycle by CA-125. The response
is confirmed by last image after ETI according to RECIST
criteria. The response duration was defined from the time of
partial response (PR) or complete response (CR) to the appear-
ance of progressive disease. Survival was measured from the
time of the initiation of ETI therapy to the time of death or
to the date of the last contact. We drew a line between sen-
sitive to platinum and resistant according to response showed
at platinum-based first-line therapy. Treatment free interval
prior to ETI (TFI) is the month(s) from the first day of last
chemotherapy cycle to the first day of ETI chemotherapy. 
Descriptive summary statistics were used to evaluate demo-
graphics and adverse events. Statistical analyses of frequency
data were performed by means of the chi-square test. OS and
response duration were measured with the Kaplan-Meier
method. P value of less than 0.05 was considered as signifi-
cant. The SPSS 11.0 (SPSS Inc., Chicago, IL, U.S.A.) was used
for statistical analysis.
RESULTS
Between March 2003 and July 2007, 43 patients enrolled
in this study. Six patients were excluded from the response
analysis but evaluable for toxicity because four patients re-
vealed unmeasurable disease on image at first ETI and two
received only one course. Therefore, thirty-seven patients re-
ceived at least two courses of treatment and were evaluable
for response and toxicity. The characteristics of the 37 pati-
ents are summarized in Table 1. The majority of the patients
(81.1%) had serous type. Thirty patients (81.1%) had initial
FIGO stage of III. 
Of the 37 patients evaluable for response, seven (18.9%)
patients showed a PR (Table 2) lasting median 7 months
(range 1-15 months), another seven (18.9%) patients had
SD and 23 (62.1%) progressed. There was no CR. Table 2
shows outcome according to clinical factors after ETI. Four
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Characteristics No. of patients %
Median age (yr), (range) 55 (34-74)
Histology
Serous 30 81.1
Clear 3 8.1
Endometrioid 2 5.4
Transitional 1 2.7
Undifferentiated 1 2.7
FIGO stage
I 1 2.7
II 2 5.4
III 30 81.1
IV 4 10.8
First-line regimen
Paclitaxel/cisplatin 23 62.2
Paclitaxel/carboplatin 8 21.6
Cyclophosphamide/cisplatin 4 10.8
Topotecan/cisplatin 1 2.7
Cyclophosphamide/adriamycin/cisplatin 1 2.7
No. of chemotherapy regimen prior to ETI
2 8 21.6
3 15 40.5
4 5 13.5
5 5 13.5
6 1 2.7
7 2 5.4
8 1 2.7
Table 1. Characteristics of patients (n=37)
ETI, etoposide and ifosfamide. of 31 (12.9%) patients with TFI <6 months had response,
while 3 of 6 patients (50%) with TFI ≥6 months had res-
ponse. The RR of patients with TFI ≥6 months was about
four times higher than that with TFI <6 months. As for ini-
tial platinum sensitivity, 30 (81%) patients were considered
clinically sensitive to platinum compounds. Most responses
(6/7) were observed in initial platinum-sensitive patients.
However, there were no significant correlations between RR
and platinum-sensitivity to first regimen (P=0.728), age (P=
0.623), and total number of regimen prior to ETI (P=0.601).
Only TFI had a significant correlation with RR (P=0.034). 
With a median follow-up of 9.2 months, median OS for
all 37 patients was 9 months (95% confidence interval: 7-
11) (Fig. 1). Seven patients with a PR had no statistical sig-
nificant (P=0.07) of survival gain (Fig. 2).
A total of 139 courses of ETI regimen were administered
to the study population. Table 3 shows the toxicity profile.
There was no treatment related death. The main hematolog-
ical toxicity was grade 3-4 neutropenia in 28 of 139 cycles
(20.1%). There were seven episodes of febrile neutropenia,
but all episodes could be managed successfully with support-
ive care. A 25% dose reduction of both drugs was needed in
four patients (10/139 courses; 7.2%) for a poor general con-
dition. There was no severe bladder toxicity and other toxic
effects were negligible.
DISCUSSION
This is phase II trial that evaluated the efficacy and toxic-
ity of ETI regimen for heavily pretreated patients with recur-
rent or persistent EOC. Five phase II studies about ETI reg-
imen in EOC have been reported to date. We summarized
the characteristics of these studies including our study (Table
4). Our study was different from the previous studies due to
the number of prior chemotherapy regimens given before ETI.
All of the trials used ETI as second- or third line of chemo-
therapy. Three of these phase II trials used IV etoposide (19-
Etoposide and Ifosfamide in Recurrent Epithelial Ovarian Cancer 947
Parameters
No. of
patients
OR, 
No (%)
OS, months
Median
(95% CI)
P value* P value
�
TFI prior to ETI
≥6 months 6 3 (50.0) 0.034 10 (7-13) 0.351
<6 months 31 4 (12.9) 4 (2-6)
Platinum sensitivity
Sensitive 30 6 (20.0) 0.728 11 (1-21) 0.064
Resistant 7 1  (14.3) 6  (3-9)
No. of chemotherapy regimen prior to ETI
2 8 1 (12.5) 0.601 7 (2-30) 0.599
3-8 29 6 (20.7) 2 (7-10)
Total 37 7 (18.9) 9 (7-11)
Table 2. Outcome according to clinical factors after etoposide
and ifosfamide chemotherapy
*chi-square; 
� Log rank.
No., number; OR, objective response (CR or PR); OS, overall survival;
CI, confidence interval; TFI, Treatment-free interval.
Fig. 1. Overall survival curve of 37 patients with a median follow-
up of 9.2 months.
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Fig. 2. Survival curves of 37 patients according to with or without
response to ETI.
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responder
nonresponder
P=0.07
Toxicities
Proportion (%) of cycles affected grade
01 234
Neutropenia 53.2 10.1 15.1 12.9 7.2
Anemia 26.6 48.2 16.5 4.3 2.9
Thrombocytopenia 82.0 2.9 5.0 5.0 3.6
SGOT/SGPT 95.7 2.9 0 0 0 
Nausea/Vomiting 46.7 50.4 2.9 0 0
BUN/Creatinine 95.7 2.9 0 0 0 
Number of patients affected grade
01 234
Alopecia 0 0 4 39 0
Peripheral neuropathy 8 33 2 0 0
Hematuria 43 0 0 0 0
Table 3. Toxicity of ETI regimen according to WHO criteria (n=
139 cycles)
ETI, etoposide and ifosfamide. 21), while the other two used oral etoposide (22, 23). Bruz-
zone et al. (20) study resulted in no responses in 12 patients
progressing or relapsing after primary cisplatin-containing
combination, Trope et al. (21) obtained the following results;
in 29 patients who received cisplatin as first-line and were
deemed to be platinum-resistant, used ETI regimen same
dose to ours, RR was 21%, the median time to disease pro-
gression was 6 months. They presumed the response to ETI
was independent of prior response to first-line cisplatin-based
chemotherapy, since there is no cross-resistance between ETI
regimen and cisplatin. Our data (Table 2) showed similar out-
comes. Therefore, there seems to be no cross-resistance bet-
ween ETI and first-line cisplatin in heavily pretreated pati-
ents. Contrary to this pilot study, they reported ETI had dis-
mal RR (6.5%) and ETI should be abandoned later (19). They
explained the reason of dismal RR of ETI could be all pati-
ents in this large study had ‘‘true’’ platinum-resistant tumors.
Additionally they introduced 1-day ETI regimen and com-
pare with 5-day regimen, which was considered by the pati-
ents better tolerated because of the shorter hospital stay. Al-
though administration dose was significantly higher in 1-day
regimen due to less dose reduction, there was no difference in
response between the two regimens. Another group obtained
the following results; in 35 platinum resistant patients who
used oral etoposide, RR was 26%, duration of response was
9 months and the median survival was 13 months (22).
Interestingly, the RR in the subgroup with TFI ≥6 months
is high (50%; median duration 7 months) and statistically
significant (P=0.034) compared to that of patients who had
TFI <6 months though the number of patients was small.
A trend appeared that the responders had survival gain (P=
0.07) (Fig. 2). Therefore, in the selected patients treated with
multiple chemotherapeutic regimens with TFI ≥6 months,
further study of ETI regimen is necessary.
In our patients, ETI regimen showed 18.9% RR. This was
not higher than that of single recurrence regimen despite the
combination chemotherapy. Some factors may be proposed
to explain. First, our group of patients had particularly unfa-
vorable clinical characteristics. In 78.3% of patients, the study
regimen was given as fourth-line chemotherapy or more and
the high proportion (84%) of the patients had TFI <6 months.
Second, the compromised bone-marrow reserve of these heav-
ily pretreated patients did not allow the administration of
the regimen as scheduled. In 31 of 139 cycles (22.3%) there
were delayed administrations for more than a week for hema-
tological recoveries and in 10 cycles (7.2%), 25% dose reduc-
tion was needed. Last, a potential mechanism for the lack of
additive or synergistic effect of adding ifosfamide to etopo-
side may stem from an observation that ifosfamide adminis-
tration with or before other chemotherapeutic agents may
actually antagonize these agents’ activity, possibly by deplet-
ing cellular glutathione (24).
Apart from effectiveness, other variables may affect the deci-
sion to select a regimen in this heavily pretreated population.
For example toxicity profile, quality of life, ease of adminis-
tration, cost issues, and residual toxicity from prior therapy
(25). Ifosfamide is the oldest group of drugs and produces less
severe hematological toxicity (17). Together with etoposide,
it produces an acceptable toxicity level with grade 3 or 4 neu-
tropenia most common in 20.1% of the patients in this study
(Table 3). Considering 29 of the 37 (78.3%) patients who
were enrolled in the current study had already been treated
with 3 or more regimens before ETI, delayed schedule of
22.3% of total 139 cycles and dose reduction of 7.2% were
not more than expected. Therefore ETI combination chemo-
therapy could be administered in heavily pretreated patients
with EOC. 
According to NCCN guideline (26), patients who are con-
sidered platinum-sensitive have the greatest number of poten-
tial options for second-line therapy. Evidence suggests that
combination chemotherapy may be superior to single-agent
therapy in platinum-sensitive group (27). Options include
carboplatin/paclitaxel (27), gemcitabine/carboplatin (28), or
a recurrence regimen. In platinum-resistant patients, retreat-
ment with a platinum compound or paclitaxel is not recom-
mended. Options include treatment with a recurrence regi-
men that does not contain platinum (4) or supportive care.
Several recurrence agents show similar effect as single regi-
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N/A, not applicable; PO, per oral; IV, intravenous; d, day.
Trope 
et al. (20)
This trial Parameters
Trope 
et al. (21)
Bruzzone
et al. (19)
Aravantinos
et al. (22)
Shaheen 
et al. (23)
No. of patients 37 29 103 12 35 14
Median age (yr) 55 53 56 N/A 65 59
No. of previous regimen ≥2 1-2 1-2  3 (in 3 patients) 1 1 1
Dosage
Etoposide (mg/m
2) 100 IV, 3 d 100 IV, 3 d 100 80 IV, 3 d 100 PO, 10 d 37.5 PO, 14 d
Ifosfamide (g/m
2) 1.0 IV, 5 d 1.0 IV, 5 d 5.0 1.5 IV, 3 d 2.25 IV, 2 d 1.2 IV, 4 d
Cycle (week) 3 3 3 3 4 4
OR, % (CR+PR) 18.9 (0+7) 21.0 (1+5) 6.5 (0+6) 0 (0+0) 26 (4+5) 14 (0+2)
Median duration of response (months) 7 6 6 N/A 9 N/A
Median survival (months) 9 12 7 N/A 13 N/A
Table 4. Previous phase II trials of etoposide and ifosfamide for recurrent epithelial ovarian cancermen: topotecan, 20% (29); gemcitabine, 19% (7, 8); vinorel-
bine, 20% (30); liposomal doxorubicin, 26% (9); oral etopo-
side, 27% (11, 12); and ifosfamide, 12% (16). Most patients
in this study were platinum-sensitive at first line chemother-
apy, therefore, received combination chemotherapy that in-
cluded topotecan, cyclophosphamide, cisplatin, carboplatin,
paclitaxel, docetaxel, and belotecan as 2nd or 3rd-line. They
did not receive gemcitabine or liposomal doxorubicin, because
medical insurance in our country did not cover these chemo-
therapeutic agents. 
In conclusion, ETI produces relatively low toxicity and
modest activity in heavily pretreated recurrent or persistent
EOC. In addition, this regimen should be further studied in
the selected patients treated with multiple chemotherapeu-
tic regimens and with TFI more than 6 months. 
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